Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIKHIL V INAMDAR

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1093723132
CMS profile
230365
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$67.35

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $67.35 4

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $38.48 2
IRONWOOD PHARMACEUTICALS, INC $15.72 1
Merck Sharp & Dohme Corporation $13.15 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIKHIL V INAMDAR

NPI 1093723132 · CMS profile ID 230365

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093723132?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIKHIL V INAMDAR, NPI 1093723132, CMS profile ID 230365. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093723132?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). NIKHIL V INAMDAR, NPI 1093723132, CMS profile ID 230365. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093723132?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
NIKHIL V INAMDAR, NPI 1093723132, CMS profile ID 230365, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1093723132?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $67.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
IRONWOOD PHARMACEUTICALS, INC $15.7202/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749808709 CMS
Merck Sharp & Dohme Corporation $13.1502/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747616517 CMS
AbbVie Inc. $20.5802/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721895535 CMS
AbbVie Inc. $17.9001/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721895531 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $254.33 18
PY2020 $67.35 4
PY2021 $70.92 5
PY2022 $780.77 31
PY2023 $1,008.25 42
PY2024 $720.37 36
PY2025 $854.66 45

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $35,696.45 10
PY2024 Principal investigator $19,138.20 3
PY2023 Principal investigator $12,650.20 5
PY2022 Principal investigator $17,963.35 8
PY2021 Recipient $480.00 1
PY2021 Principal investigator $128,158.76 43
PY2020 Principal investigator $146,255.72 108
PY2019 Recipient $18,259.37 8
PY2019 Principal investigator $239,865.67 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,251.00 12/16/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792487551
Principal investigator 1 Roche Products Limited $4,000.00 12/07/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 836026105
Principal investigator 1 ABBVIE INC. $114.75 12/02/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792485165
Principal investigator 1 ABBVIE INC. $101.25 11/17/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792483107
Principal investigator 1 ABBVIE INC. $1,974.80 11/17/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792483109
Principal investigator 1 ABBVIE INC. $2,513.00 10/20/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 792480049
Principal investigator 1 ABBVIE INC. $1,495.35 10/14/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792479425
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,753.50 10/05/2021 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 816764239
Principal investigator 1 ABBVIE INC. $2,562.65 09/09/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792475031
Principal investigator 1 ABBVIE INC. $530.70 09/07/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792474107
Principal investigator 1 ABBVIE INC. $2,241.20 08/30/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792473209
Principal investigator 1 ABBVIE INC. $750.00 07/29/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792470337
Principal investigator 1 ABBVIE INC. $2,039.85 07/29/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792470339
Principal investigator 1 ABBVIE INC. $5,348.65 07/29/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792470341
Recipient Braintree Laboratories, Inc. $480.00 07/06/2021 Covered Recipient Physician BLI4900-302 No dispute reported 06/30/2026 805278797
Principal investigator 1 Braintree Laboratories, Inc. $480.00 07/06/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805281441
Principal investigator 1 ABBVIE INC. $2,945.05 06/30/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792465329
Principal investigator 1 ABBVIE INC. $300.00 06/23/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792463875
Principal investigator 1 Allergan, Inc. $1,659.30 06/23/2021 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789019463
Principal investigator 1 ABBVIE INC. $300.00 06/21/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792463575
Principal investigator 1 Braintree Laboratories, Inc. $2,000.00 06/14/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805281339
Principal investigator 1 Braintree Laboratories, Inc. $1,063.00 06/14/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805281345
Principal investigator 1 Braintree Laboratories, Inc. $450.00 06/14/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805281351
Principal investigator 1 Braintree Laboratories, Inc. $138.00 06/14/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805281357
Principal investigator 1 Braintree Laboratories, Inc. $3,965.82 06/14/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805281363
Principal investigator 1 ABBVIE INC. $300.00 06/09/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 792462779
Principal investigator 1 ABBVIE INC. $300.00 06/09/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease Who Failed Prior Biologic Treatment No dispute reported 06/30/2026 792462801
Principal investigator 1 ABBVIE INC. $300.00 06/09/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792462807
Principal investigator 1 ABBVIE INC. $300.00 06/09/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792462821
Principal investigator 1 Braintree Laboratories, Inc. $80.00 06/03/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805280945
Principal investigator 1 ABBVIE INC. $2,993.65 05/27/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792460751
Principal investigator 1 Braintree Laboratories, Inc. $3,454.38 05/21/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805280575
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $798.00 05/18/2021 Non-covered Recipient Entity
TX DIGESTIVE DISEASE CONSULTANTS
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 816724653
Principal investigator 1 Allergan, Inc. $30.00 05/01/2021 Non-covered Recipient Entity
GI LIVER RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789019461
Principal investigator 1 ABBVIE INC. $8,383.08 04/30/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792452353
Principal investigator 1 ABBVIE INC. $2,671.65 03/30/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792438037
Principal investigator 1 Braintree Laboratories, Inc. $12,700.00 03/12/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805279857
Principal investigator 1 Braintree Laboratories, Inc. $14,876.28 03/12/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805279863
Principal investigator 1 ABBVIE INC. $1,308.00 03/02/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792429795
Principal investigator 1 ABBVIE INC. $10,581.63 03/02/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792429801
Principal investigator 1 Braintree Laboratories, Inc. $17,361.72 01/29/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS - WEBSTER
BLI4900-302 No dispute reported 06/30/2026 805279449
Principal investigator 1 ABBVIE INC. $8,979.00 01/28/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792416115
Principal investigator 1 ABBVIE INC. $2,463.50 01/28/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792416121
Principal investigator 1 Roche Products Limited $300.00 01/07/2021 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836025977

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $30,371.83 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $30,371.83 1
PY2022 Amount invested $345.82 1
PY2022 Value of interest $1,907.69 1
PY2021 Amount invested $1,247.84 1
PY2021 Value of interest $1,560.22 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2021–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 GastroGPO, LLC $0.00 $30,371.83 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124819083
PY2023 GastroGPO, LLC $0.00 $30,371.83 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1050730035
PY2022 GastroGPO, LLC $345.82 $1,907.69 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 955000235
PY2021 GastroGPO, LLC $1,247.84 $1,560.22 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 854913835